Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 4/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15996597 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL19296178 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL14899628 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL16004567 | 0.85 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL1572414 | 0.79 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL1273472 | 0.79 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL29102312 | 0.79 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL19664035 | 0.79 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL20773468 | 0.79 | CHRM2 (0.49) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL18023493 | 0.79 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CHRM2 4782/4885CHRM1 4747/4885CHRM3 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.